drugset / Trial / NCT01521364
Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
NaSingle-groupOpen-labelTreatment
Summary
Future patients might benefit from a combination of linezolid (LIN) and clarithromycin (CLA) in the treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) due to possible synergistic activity as shown in in vitro experiments in different Mycobacteria strains. The investigators observed increased LIN serum levels in three cases after combining LIN and CLA of which the investigators described one in a case report (Bolhuis et al). The investigators suggest to conduct a prospective pharmacokinetic study in MDR- and XDR-TB patients to quantify the above described interaction between LIN and CLA.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-10
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 250 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |